These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23865680)

  • 21. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
    Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
    Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active site similarity between human and Plasmodium falciparum phosphodiesterases: considerations for antimalarial drug design.
    Howard BL; Thompson PE; Manallack DT
    J Comput Aided Mol Des; 2011 Aug; 25(8):753-62. PubMed ID: 21766240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
    Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of Free Energy Perturbation (FEP+) to Understanding Ligand Selectivity: A Case Study to Assess Selectivity Between Pairs of Phosphodiesterases (PDE's).
    Moraca F; Negri A; de Oliveira C; Abel R
    J Chem Inf Model; 2019 Jun; 59(6):2729-2740. PubMed ID: 31144815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
    Card GL; Blasdel L; England BP; Zhang C; Suzuki Y; Gillette S; Fong D; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
    Nat Biotechnol; 2005 Feb; 23(2):201-7. PubMed ID: 15685167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach.
    Gadhe CG; Kothandan G; Cho SJ
    J Biomol Struct Dyn; 2013; 31(11):1251-76. PubMed ID: 23153179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay.
    Li Z; Cai YH; Cheng YK; Lu X; Shao YX; Li X; Liu M; Liu P; Luo HB
    J Chem Inf Model; 2013 Apr; 53(4):972-81. PubMed ID: 23517293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
    Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
    Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
    Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
    Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology.
    Wayman C; Phillips S; Lunny C; Webb T; Fawcett L; Baxendale R; Burgess G
    Int J Impot Res; 2005; 17(3):216-23. PubMed ID: 15800654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.
    Maw GN; Allerton CM; Gbekor E; Million WA
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1425-8. PubMed ID: 12668004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization.
    Weeks JL; Zoraghi R; Francis SH; Corbin JD
    Biochemistry; 2007 Sep; 46(36):10353-64. PubMed ID: 17696499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
    Zhu J; Yang Q; Dai D; Huang Q
    J Am Chem Soc; 2013 Aug; 135(32):11708-11. PubMed ID: 23899287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
    Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
    Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
    Sung BJ; Hwang KY; Jeon YH; Lee JI; Heo YS; Kim JH; Moon J; Yoon JM; Hyun YL; Kim E; Eum SJ; Park SY; Lee JO; Lee TG; Ro S; Cho JM
    Nature; 2003 Sep; 425(6953):98-102. PubMed ID: 12955149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
    Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
    Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
    Vlasceanu A; Jessing M; Kilburn JP
    Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism.
    Schwan G; Barbar Asskar G; Höfgen N; Kubicova L; Funke U; Egerland U; Zahn M; Nieber K; Scheunemann M; Sträter N; Brust P; Briel D
    ChemMedChem; 2014 Jul; 9(7):1476-87. PubMed ID: 24729456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.